Covid-19: $30 bn needed to develop tests, treatments, vaccines, says WHO

The WHO is working with a large coalition of drug-development, funding and distribution organisations under what it calls the ACT-Accelerator Hub

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
The initiative is intended to develop and deliver 500 million Covid-19 tests and 245 million courses of new treatment for the disease
Reuters
2 min read Last Updated : Jun 27 2020 | 2:02 AM IST
A World Health Organization-led coalition fighting the Covid-19 pandemic is asking government and private sector donors to help raise $31.3 billion in the next 12 months to develop and deliver tests, treatments and vaccines for the disease.

Renewing its call on Friday for global collaboration against the pandemic, it said $3.4 billion had been contributed for the coalition to date, leaving a funding gap of $27.9 billion. Of that, $13.7 billion was "urgently needed".

The WHO is working with a large coalition of drug-development, funding and distribution organisations under what it calls the ACT-Accelerator Hub.

The initiative is intended to develop and deliver 500 million Covid-19 tests and 245 million courses of new treatment for the disease to low- and middle-income countries by mid-2021, it said in a statement.

It also hoping 2 billion vaccines doses, including 1 billion to be bought by low- and middle-income countries, will be available by the end of 2021.
The ACT-Accelerator was launched in April to speed up research and development work on medical tools to tackle Covid-19. On Friday, the WHO said the pandemic was still threatening millions of lives and scores of economies, and urgent work and funds were needed.

"The investment required is significant, but it pales in significance when compared to the cost of Covid-19," it said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineWorld Health Organisation

Next Story